Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

EGFR inhibitor

- PMLiVE

Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS

If approved, this treatment would offer a new option for the nearly one million Americans living with MS

HCP engaging with elderly patient

Long-term clinical trial engagement is a behavioural challenge – not just an informational one

Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.

Cuttsy + Cuttsy

- PMLiVE

Smarter science, sharper strategy: Expert insights from ASCO® 2026

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

Inizio

Doctor sitting with patient

Patients are telling the truth — just not to you

Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.

Cuttsy + Cuttsy

- PMLiVE

Roche and Dualitas Therapeutics announce research collaboration worth up to $1bn

The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases

Group of women smiling

When what matters to patients is hard to measure

Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.

Cuttsy + Cuttsy

- PMLiVE

AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer

The results from a global phase 3 trial show the longest survival data ever reported in this setting

- PMLiVE

Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments

MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain

- PMLiVE

Novartis announces trial results for remibrutinib in relapsing multiple sclerosis

MS affects nearly three million people worldwide and has three main types

Doctor speaking to patient

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

Cuttsy + Cuttsy

- PMLiVE

AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo

Rinvoq is the first and only systemic medication approved in the EU for NSV

- PMLiVE

Pfizer announces phase 3 results for nonsegmental vitiligo treatment

Litfulo delivered significant, clinically meaningful improvements for both face and body

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links